drugset / Trial / NCT05306353
CD40L Antagonism in Rheumatoid Arthritis (RA)
Phase 2
Terminated
2 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Timeline
- Start
- 2023-07-25
- Primary completion
- 2025-07-28
- Completion
- 2025-07-28
Outcome
Outcome not reported
Stopped (Enrollment): “The study is being closed early due to insufficient participant enrollment across study sites.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dazodalibep | Protein / enzyme biologic | 1500 mg | Intravenous |